RxDoctor Payments Data

Samantha Jacinto

Physician Assistant · la Habra, CANPI 1932760857

Payments from drug & device makers

$5,074in general payments, 2019–2025

Across 245 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$650
  • GSK$633
  • Astellas Pharma US Inc$424
  • Biohaven Pharmaceutical Holding Company Ltd.$422
  • Boehringer Ingelheim$382
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,97998%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,074 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$30,996
Medicare patients
166
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$46,518
TrulicityDulaglutide25$40,782
OzempicSemaglutide17$24,160
EliquisApixaban19$18,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,199
MyrbetriqMirabegron15$12,897
FarxigaDapagliflozin Propanediol13$10,216
Atorvastatin Calcium191$2,429
Levothyroxine Sodium163$1,790
Albuterol Sulfate HfaAlbuterol Sulfate48$1,354
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,226
Olmesartan Medoxomil61$1,190
Estradiol12$1,029
Omeprazole92$921
Tamsulosin Hcl78$890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$382$46,51838 claims
Lilly USA, LLCTrulicity$1,088$40,78225 claims
Novo NordiskOzempic$357$24,16017 claims
PfizerEliquis$225$18,38619 claims
GSKTrelegy Ellipta$633$15,19924 claims
Astellas Pharma US IncMyrbetriq$424$12,89715 claims
AstraZenecaFarxiga$195$10,21613 claims
AbbVieSynthroid$650$85912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in la Habra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →